GeneDx Holdings Corp. - Class A Common Stock (WGS)
42.13
+0.00 (0.00%)
NASDAQ· Last Trade: May 20th, 5:22 AM EDT
Detailed Quote
Previous Close
42.13
Open
-
Bid
38.50
Ask
44.00
Day's Range
N/A - N/A
52 Week Range
32.21 - 170.87
Volume
1,124
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,869,608
Chart
About GeneDx Holdings Corp. - Class A Common Stock (WGS)
GeneDx Holdings Corp. is a genomics company that specializes in providing genetic testing services to aid in the diagnosis and treatment of various genetic disorders. By leveraging advanced genomic technologies and bioinformatics, the company aims to deliver accurate and comprehensive genetic information that helps clinicians make informed decisions about patient care. GeneDx focuses on enhancing the understanding of rare and hereditary diseases, facilitating personalized medicine, and improving patient outcomes through insightful genomic data services. Read More
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GeneDx (WGS) To Contact Him Directly To Discuss Their Options
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GeneDx (WGS) To Contact Him Directly To Discuss Their Options
The law firm of Kirby McInerney LLP is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of investors concerning the Company’s possible violations of federal securities laws.
GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the first quarter of 2026.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating results at 4:30 p.m. Eastern Time.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and intellectual disability (DD/ID). The data was unveiled today at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting in Baltimore, MD.
